BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 23, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2006

View Archived Issues

Leuprolide beneficial in phase II Alzheimer's disease study

Read More

Phase II studies show anemia correction with CERA in chronic kidney disease

Read More

Phase IIa study of LAB CGRP begins enrollment

Read More

Chimerix signs CRADA with U.S. Army for smallpox therapeutic CMX-001

Read More

Enrollment begins in phase III Bronchitol study

Read More

Vectura to work with Boehringer Ingelheim on dry powder inhaler

Read More

CEL-1000 shows adjuvant activity with malaria vaccines

Read More

ACP-103 increases slow wave sleep in clinical study

Read More

Pilot study of MM-093 in psoriasis completes enrollment

Read More

Bio-E-Gel NDA accepted for review

Read More

End of phase II testing of diquafosol in Asia triggers milestone payment

Read More

Enrollment completed in pivotal study of IL-Trap for CAPS

Read More

Stressgen to focus on reformulated HspE7

Read More

NIAID funds development of VivaGel for genital herpes

Read More

New evidence that selective M3 muscarinic antagonists can inhibit tumor growth

Read More

Feeding-suppressive properties of new orally active NPY Y5 antagonist

Read More

Antiangiogenic efficacy of a new multiple RTK inhibitor from Roche

Read More

Endocyte investigates folate-targeted cytotoxic anticancer drug in phase I study

Read More

Meditor begins phase II trial for MTR-104 in intradialytic hypotension

Read More

Yaz now available

Read More

Alteon and HaptoGuard to merge

Read More

Takeda and Lilly conclude U.S. Actos marketing collaboration

Read More

Pozen completes SPA for PN-200

Read More

European Commission approves Prograf for use in heart transplantation

Read More

Recent patents cover therapeutic agents for neurological disorders

Read More

Novel treatment options for endocrine-related disorders disclosed in recent patents

Read More

Therapeutic agents for cardiovascular disorders disclosed in recent patents

Read More

Dual muscarinic M3 receptor antagonists and PDE4 inhibitors potentially effective for COPD

Read More

Novel agent for the management of acute renal failure in sepsis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 22, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing